# Alla Zamarayeva

> Alla Zamarayeva is the co-founder and CEO of CellFE, a Bay Area biotech building a non-viral, microfluidics-based platform for engineering human cells. A UC Berkeley engineering PhD and former Goldwater Scholar, she spun a piece of academic research she stumbled onto during her doctorate into a company aiming to make cell therapies cheaper, gentler, and eventually available at the point of care. In 2023 she led CellFE to a $22 million Series A backed by M Ventures, and she is steering the company toward redefining how gene-edited cell therapies are manufactured.

- **Role:** Co-founder and CEO at CellFE
- **Organizations:** CellFE (Cell Fluidics Engineering), UC Berkeley (alumna)
- **Nationality:** United States
- **Education:** PhD, Engineering, University of California, Berkeley, BE, Chemical Engineering, Grove School of Engineering, City College of New York (CCNY), BBA, Business Administration, International Christian University (ICU)
- **Known for:** Co-founded and leads CellFE, a non-viral microfluidic cell engineering company, Raised a $22 million Series A led by M Ventures (2023), Former Goldwater Scholar

## Career timeline

- **2011-2013** — Goldwater Scholar affiliated with the CUNY Energy Institute
- **2013** — Research intern at The Benjamin Levich Institute and at Princeton University
- **2014-2019** — William S. Floyd Jr. Fellow at UC Berkeley College of Engineering while earning her PhD
- **2018** — Co-founds CellFE with Alex Alexeev, Anna Liu, and Todd Sulchek
- **2019** — Becomes Co-founder and CEO of CellFE
- **2023** — Leads CellFE's $22M Series A, led by M Ventures with GreatPoint Ventures and Riverine Ventures
- **2025** — Announces strategic collaboration with Made Scientific to advance non-viral gene editing for T cell therapies

## Achievements

- Co-founded and leads CellFE, a non-viral microfluidic cell engineering company
- Raised a $22 million Series A led by M Ventures (2023)
- Former Goldwater Scholar
- William S. Floyd Jr. Graduate Fellow at UC Berkeley
- Work featured in Scientific American and Discover magazine
- Presented in the Startup Showcase at the ASGCT Annual Meeting

## Latest updates

- **2025-05** — CellFE announced a strategic collaboration with Made Scientific to evaluate non-viral and hybrid gene editing workflows for autologous and allogeneic T cell therapies, with results planned for a white paper by late 2025.
- **2023-09** — CellFE closed a $22M Series A led by M Ventures to advance its microfluidics-based cellular engineering platform.

## Links

- Website: https://cellfebiotech.com
- LinkedIn: http://www.linkedin.com/in/alla-zamarayeva-phd-3a495a38
- Twitter/X: https://twitter.com/cellfebiotech

---

Profile page: https://yespress.io/alla-zamarayeva
Published by YesPress — https://yespress.io
Last updated: 2026-06-14